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Rapid Effects of a Protective O-Polysaccharide-Specific Monoclonal
IgA on Vibrio cholerae Agglutination, Motility, and Surface
Morphology
Kara J. Levinson,a,b Magdia De Jesus,a Nicholas J. Mantisa,b
Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USAa; Department of Biomedical Sciences, University at
Albany, Albany, New York, USAb
2D6 is a dimeric monoclonal immunoglobulin A (IgA) specific for the nonreducing terminal residue of Ogawa O-polysaccharide
(OPS) of Vibrio cholerae. It was previously demonstrated that 2D6 IgA is sufficient to passively protect suckling mice from oral
challenge with virulent V. cholerae O395. In this study, we sought to define the mechanism by which 2D6 IgA antibody protects
the intestinal epithelium from V. cholerae infection. In a mouse ligated-ileal-loop assay, 2D6 IgA promoted V. cholerae aggluti-
nation in the intestinal lumen and limited the ability of the bacteria to associate with the epithelium, particularly within the
crypt regions. In vitro fluorescence digital video microscopy analysis of antibody-treated V. cholerae in liquid medium revealed
that 2D6 IgA not only induced the rapid (5- to 10-min) onset of agglutination but was an equally potent inhibitor of bacterial
motility. Scanning electron microscopy showed that 2D6 IgA promoted flagellum-flagellum cross-linking, as well as flagellar
entanglement with bacterial bodies, suggesting that motility arrest may be a consequence of flagellar tethering. However,
monovalent 2D6 Fab fragments also inhibited V. cholerae motility, demonstrating that antibody-mediated agglutination and
motility arrest are separate phenomena. While 2D6 IgA is neither bactericidal nor bacteriostatic, exposure of V. cholerae to 2D6
IgA (or Fab fragments) resulted in a 5-fold increase in surface-associated blebs, as well an onset of a wrinkled surface morpho-
type. We propose that the protective immunity conferred by 2D6 IgA is the result of multifactorial effects on V. cholerae, includ-
ing agglutination, motility arrest, and possibly outer membrane stress.
Cholera is a life-threatening disease that remains endemic inmany parts of the world (1–3). The etiological agent of chol-
era, Vibrio cholerae, is a noninvasive, Gram-negative bacterium
that is acquired by humans via the fecal-oral route. Following
ingestion, V. cholerae colonizes the mucosal surfaces of the small
intestines, a process that is facilitated by the bacterium’s single
polar flagellum (4–7). Adherence to the epithelial surface requires
expression of the toxin-coregulated pilus (TCP), in addition to
other virulence factors (8), most notably, a potent ADP-ribosylat-
ing toxin known as cholera toxin (CT). CT disrupts chloride se-
cretion within intestinal epithelial cells, inducing profuse water
and electrolyte secretion and ultimately resulting in the hallmark
“rice water diarrhea” associated with cholera. Cholera outbreaks
frequently occur when water sanitation is disrupted, either follow-
ing natural disasters or seasonally in areas where V. cholerae is
endemic (9). The recent cholera outbreak in Haiti following the
2010 earthquake highlighted the ongoing potential of V. cholerae
to cause mass causalities, as it resulted in more than half a million
infected individuals and more than 7,000 deaths (10). Due to the
rapid onset of symptoms and limited treatment options, control
of cholera in many parts of the globe, particularly where it is en-
demic, will be achieved only through vaccination (10).
Immunity to V. cholerae is primarily antibody mediated. While
natural V. cholerae infection, as well as oral vaccination, induces
both IgA and IgG antibody responses, secretory IgA (S-IgA) anti-
bodies directed against bacterial surface antigens, especially lipo-
polysaccharide (LPS) are considered the primary determinants of
protection (1, 9). Work by the laboratories of John Mekalanos and
Marian Neutra more than 20 years ago established that IgA anti-
bodies alone, when actively transported or passively applied into
the intestinal lumen, are sufficient to protect suckling mice from
lethal V. cholerae challenge (11, 12). Protection was associated
with antibodies directed against LPS and not CT, even though
antitoxin antibodies were able to neutralize CT in vitro (11). Oth-
ers have confirmed the importance of LPS-specific IgA in interfer-
ing with V. cholerae colonization of the intestinal epithelium in the
neonatal mouse model and with tissue section overlay assays (13–
16). LPS-specific fecal IgA levels are also implicated as a primary
correlate of immunity to V. cholerae in humans (3, 17–19).
Despite the evidence that LPS-specific IgA antibodies play a
central role in protective immunity to V. cholerae, it is still not
clear how they impede the ability of the bacterium to colonize the
intestinal epithelium. IgA is not vibriocidal, nor does it promote
Fc-mediated uptake of opsonized bacteria in the intestinal lumen
(12). LPS-specific IgA antibodies, however, are effective at pro-
moting bacterial agglutination in vitro, which led Winner and col-
leagues to propose that IgA might aggregate and entrap vibrios in
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the intestinal lumen and thereby limit their access to the epithelial
surface through a phenomenon known as immune exclusion
(12, 20).
There is emerging evidence to suggest that protective anti-LPS
IgA antibodies may have direct effects on microbial virulence,
independent of agglutination (20–24). In the case of V. cholerae,
Bishop and Camilli demonstrated using dark-field microscopy
that polyclonal anti-LPS IgA antibodies inhibit V. cholerae motil-
ity in vitro, an observation that has been confirmed by others (13,
14). Visually, IgA-mediated motility arrest of V. cholerae occurred
before the bacteria became agglutinated, suggesting that the two
phenomena are distinct. In the case of Salmonella enterica serovar
Typhimurium, we reported in 2008 that treatment of S. Typhimu-
rium with a protective O-antigen-specific IgA monoclonal anti-
body (MAb) known as Sal4 results in the immediate arrest of
flagellum-based motility, independent of agglutination (23).
More recently we demonstrated that Sal4 triggers a reduction in
type 3 secretion system (T3SS) activity and alterations in outer
membrane integrity and onset of exopolysaccharide (EPS) pro-
duction. From these data, we have postulated that Sal4 triggers an
outer membrane stress response in S. Typhimurium that tempo-
rarily renders the bacterium avirulent (24). We are only beginning
to investigate whether LPS-specific IgA antibodies have similar
effects on other enteric pathogens.
In this report, we have probed the interaction between V. chol-
erae and 2D6, a murine IgA MAb directed against the immuno-
dominant nonreducing terminal residue of Ogawa O-polysaccha-
ride (OPS) (9, 11, 12, 25). 2D6 was the first IgA MAb shown to be
sufficient to protect suckling mice from a lethal challenge of V.
cholerae (12). Here we provide evidence that 2D6 limits V. cholerae
colonization of the intestinal epithelium through a combination
of agglutination, antibody-mediated motility arrest, and, possibly,
even outer membrane stress.
(Parts of this work were presented at the 114th General Meet-
ing of the American Society for Microbiology, Boston, MA, May
2014 [26].)
MATERIALS AND METHODS
Bacterial strains and growth conditions. All strains used in this study are
derivatives of the V. cholerae O1 classical strain O395, which was a gift
from John Mekalanos (Harvard Medical School) (27). Strain RT4273
consists of V. cholerae O395 containing the plasmid pGreenTIR (28) and
was kindly provided by Ronald Taylor (Dartmouth Medical School).
Strains were grown in LB medium at 37°C with aeration (150 rpm) sup-
plemented when necessary with ampicillin (100 g/ml).
Antibodies. Rabbit polyclonal antisera against the V. cholerae Inaba
and Ogawa antigens were purchased from BD Difco (Franklin Lakes, NJ)
and dialyzed against phosphate-buffered saline (PBS) with a Slide-A-
Lyzer (10,000-molecular-weight cutoff; Pierce Scientific, Rockford, IL)
prior to use. The monoclonal dimeric IgA antibodies Sal4 (specific for the
Salmonella enterica serovar Typhimurium O5 antigen) (29) and 2D6 (spe-
cific for V. cholerae OPS) (12) were obtained from Marian Neutra (Chil-
dren’s Hospital, Boston, MA). Sal4 and 2D6 hybridomas were maintained
in CD hybridoma serum-free, protein-free medium (Gibco-Invitrogen,
Carlsbad, CA) without antibiotics at 37°C in a 5% CO2–95% air atmo-
sphere, as described previously (23). The concentrations of Sal4 and 2D6
were determined by sandwich enzyme-linked immunosorbent assay with
IgA TEPC-15 (Sigma-Aldrich, St. Louis, MO) as a standard. As mouse IgA
is refractory to protease digestion with papain, Fab fragments were gen-
erated from a recombinant chimeric derivative of 2D6 in which the mouse
heavy- and light-chain (HL) variable regions were grafted onto an IgG1
backbone (K. Levinson, M. Pauly, K. Whaley, L. Zeitlin, and N. Mantis,
unpublished data). Fab fragments of chimeric 2D6 IgG were produced
using the IgG Fab preparation kit (ThermoScientific, Rockford, IL). SDS-
PAGE and GelCode Blue (ThermoScientfic) staining were used to con-
firm that MAb 2D6 IgG was digested to completion. Fab fragments were
measured by NanoDrop (ThermoScientific, Wilmington, DE) to deter-
mine the concentration.
Mouse ligated-ileal-loop assays. Female BALB/c mice (5 to 8 weeks
old) were obtained from Taconic (Hudson, NY). Animals were housed
under conventional specific-pathogen-free conditions and were
treated in compliance with the Wadsworth Center’s Institutional An-
imal Care and Use Committee (IACUC) guidelines. The ligated-ileal-
loop assays were conducted essentially as described previously (30).
Briefly, mice under isoflurane anesthesia were subjected to a laparot-
omy to expose a 1- to 2-cm segment of the ileum containing a single
Peyer’s patch. V. cholerae O395 (1.5 108 cells/0.2 ml) mixed with the
indicated MAbs or Fab fragments (9 g/ml) and was injected into the
ligated ileal loops. After 30 min, the animal was euthanized, and intestinal
segments were removed, embedded in OCT medium, and snap-frozen in
liquid nitrogen (31). Serial cryosections (25 m) of frozen tissue were
prepared using a Reichert-Jung 2800e cryostat (Leica, Wetzlar, Germany)
and stained. For each experiment, we used at least two mice per treatment
group (e.g., control, Sal4, and 2D6), and the experiments were repeated
three independent times.
To detect V. cholerae, we stained the tissue with polyclonal rabbit
anti-LPS antisera (BD, Sparks, MD) and used goat anti-rabbit Alexa Fluor
546 IgG (HL) (Molecular Probes, Eugene, OR) as a secondary antibody.
To stain for dendritic cells, we used anti-mouse CD11c-allophycocyanin
(APC) conjugate clone N418 (eBioscience, San Diego, CA). Sections were
visualized using a Leica SP5 confocal laser scanning microscope (Leica,
Wetzlar, Germany) and processed using Fiji (ImageJ) software version
1.49f (32). Montage confocal images were generated using Adobe Photo-
shop version 13.0 32 (San Jose, CA).
V. cholerae motility and agglutination assays. V. cholerae liquid mo-
tility assays were conducted as follows. Mid-log-phase cultures of strain
RT4273 were treated with the indicated MAbs (15 g/ml) and then spot-
ted (30 l) onto glass microscope slides with a coverslip. The slides were
immediately mounted on a Nikon TI inverted microscope equipped with
a CoolSnap HQ2 camera (Photometrics, Tucson, AZ). In an effort to
minimize the photon dose to the bacteria, the illumination was shuttered,
and we used a monochrome camera. Cells were imaged using a 60
objective (1.4 NA) with immersion oil and monitored for a total of 30
min. Every 5 min, we acquired three videos, each containing 100 image
sequences (110 ms of exposure/frame). Within each 100-frame video,
frames 20 to 25, 60 to 65, and 80 to 85 were visualized using Fiji software
version 1.49f (32). Motility was determined by manually tracking individ-
ual bacteria across each of the six-frame snapshots. We used the mean
fluorescence intensity (MFI) determinations of bacterial clusters to esti-
mate the degree of bacterial agglutination in each of the six-frame snap-
shots. The video microscopy experiments were conducted three indepen-
dent times, and then the results were averaged.
SEM. For scanning electron microscopy (SEM), mid-log-phase cul-
tures of V. cholerae O395 were diluted 1:50 into 2 ml of LB broth contain-
ing 9 g/ml of Sal4 IgA, 2D6 IgA, 2D6 IgG, or 2D6 Fab fragments and
incubated at 37°C for 20, 60, or 120 min with aeration (150 rpm). Samples
were captured on 0.2-m-pore polycarbonate filters using a vacuum ap-
paratus and fixed with 2% glutaraldehyde for 20 min, washed with PBS
and sterile water, and then subjected to a series of ethanol dehydrations (5
min each). The samples were critical point dried, mounted on aluminum
studs with carbon paste, and sputter coated with gold for 45 s. Samples
were imaged on a Zeiss Neon-40 EsB FIB-SEM.
RESULTS
2D6 IgA promotes V. cholerae agglutination and interferes with
epithelial attachment in a mouse ligated-ileal-loop model. To
examine whether 2D6 IgA interfered with the ability of V. cholerae
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cells to adhere to and colonize the intestinal epithelium, strain
O395 was mixed with 2D6 or the S. Typhimurium-specific IgA
antibody Sal4 as an isotype control and then injected into mouse
ligated ileal loops. In control samples, we observed V. cholerae
situated within the intestinal lumen as well as in close proximity to
the villus epithelium. In the lumen, bacteria were uniformly dis-
tributed throughout and were rarely aggregated or clumped (Fig.
1A). In proximity to the epithelium, bacteria were concentrated at
the tips of villi (likely within the mucus) as well as lower aspects of
villi and crypts. V. cholerae was occasionally observed associated
with the follicle-associated epithelium (FAE) of Peyer’s patches. In
contrast, 2D6-treated bacteria were retained in the intestinal lu-
men, either as large aggregates or as clusters of cells (Fig. 1B).
Although the ligated-ileal-loop assay was not quantitative, we
noted (based on relative fluorescence intensity) that bacteria
treated with 2D6 were less frequently associated with the intestinal
epithelium or crypts than the control Sal4-treated bacteria. These
data demonstrate that 2D6 interferes with the ability of V. cholerae
to adhere to the intestinal epithelium.
2D6 IgA promotes V. cholerae agglutination and motility
arrest in vitro. Having demonstrated that 2D6 promotes bac-
terial agglutination within the intestinal lumen, we postulated
that the antibody might have additional effects on the capacity
of V. cholerae to colonize epithelial surfaces. Bishop and Camilli
reported that polyclonal LPS-specific IgA antibodies were potent
inhibitors of V. cholerae motility (13). To determine if 2D6 IgA has
an effect on V. cholerae motility, mid-log-phase cultures of green
fluorescent protein (GFP)-expressing strain RT4273 were treated
with 2D6, spotted onto glass microscope slides, and imaged by
digital video fluorescence microscopy. In untreated control cul-
FIG 1 2D6 IgA reduces V. cholerae attachment to epithelial surfaces in vivo. V. cholerae O395 was either untreated (A) or treated with 2D6 IgA (B) or 2D6 Fab
fragments (C) and injected into 1-cm ligated ileal loops of BALB/c mice, as described in Materials and Methods. After 30 min, the loops were excised, frozen,
cryosectioned, and stained with fluorescently labeled V. cholerae antiserum (red) or CD11c (blue) to detect mucosal dendritic cells (DCs). Stained cryosections
were then visualized by confocal microscopy. In each case, the panels in the right-hand column are zoomed-in images of the panels in the left-hand columns. In
panels A, V. cholerae was observed in close association with the epithelium (arrows) and penetrating the intestinal crypts (arrowheads). In panels B, 2D6
IgA-treated bacteria were largely aggregated in the lumen (arrows) and rarely in the crypts (arrowheads). In panels C, 2D6 Fab fragment-treated V. cholerae cells
were observed in close association with villus epithelium and in the crypts (arrowhead). Scale bars, left column, 300 m; right column, 50 m. Abbreviations: PP,
Peyer’s patches; V, villi; L, lumen.
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tures, V. cholerae remained motile (95%) and free of any detect-
able agglutination for the entire 30-min observation period (Fig.
2; see Movie S1 in the supplemental material). The addition of
Sal4 as an IgA isotype control did not influence V. cholerae motil-
ity or agglutination (data not shown). In contrast, 2D6 IgA treat-
ment resulted in a rapid and dose-dependent inhibition of V. chol-
erae motility that occurred in advance of or concordant with the
onset of agglutination (Table 1 and Fig. 2; see Movie S2 in the
supplemental material). By 5 min, 85% of the cells in culture
were immobilized: approximately half of the nonmotile bacteria
were associated with clusters consisting of 3 to 10 bacterial bod-
ies, while the remainder were single cells. Most notably, we ob-
served numerous single cells that rapidly transitioned from motile
to nonmotile upon antibody treatment, a finding that supports
the claim of Bishop and Camilli that motility arrest can occur
independently of agglutination (13). Furthermore, we observed
bacteria wriggling within the clusters, suggesting that flagellar ro-
tation is not fully extinguished even when the cells are bound to
each other (Table 1 and Fig. 2; see Movie S2). By 30 min, virtually
all cells within the 2D6 IgA-treated cultures were amassed into
large macroscopic aggregates and were completely devoid of
movement. Collectively, these data demonstrate that 2D6 IgA-
mediated agglutination and motility arrest of V. cholerae occur
rapidly and are likely distinct phenomena.
FIG 2 2D6 IgA rapidly inhibits V. cholerae motility in liquid media. A mid-log-phase culture of V. cholerae strain RT4273 was treated with 2D6 IgA or 2D6 Fab
fragments, spotted onto a microscope slide, mounted on Nikon TI inverted microscope equipped with a CoolSnap HQ2 digital camera, and imaged for 20 min,
as described in Materials and Methods. (A) Quantitation (percentage) of the number of motile and nonmotile cells at each time point following antibody
treatment. There was a significant reduction (P  0.01, Student’s t test) in bacterial motility following treatment of V. cholerae with 2D6 IgA or 2D6 Fab fragments
at all time points examined compared to control (untreated) cells. (B) Assessment of bacterial agglutination by measurement of mean fluorescent intensity (MFI)
following 2D6 IgA treatment. In the absence of 2D6 IgA, there was no measurable agglutination. Student’s t test was used to determine significance (*, P  0.05;
***, P  0.0003).
TABLE 1 Differential impact of different 2D6 antibody types on V. choleraea
2D6 antibody type Valency Agglutination
Motility
SEM resultd
Semisolid
agarb
Liquid
mediumc
IgA 4    W, B, T
IgG1 2    W, B, T
Fab fragments 1 	   W, B
a Mid-log-phase cultures of V. cholerae strain RT4273 were mixed with 2D6 antibody (9 g/ml) and visualized by confocal microscopy after 30 min of incubation. The degree of
agglutination or motility arrest was scored as follows: , 85%; , 70%; , 50%; , 20%; 	, 0%.
b V. cholerae O395 was stabbed into 0.3% semisolid agar containing 2D6 antibody (9 g/ml) and then incubated at 37°C. Migration away from the stab site was measured after 8 h
of incubation at 37°C. The values indicate the degree to which the different antibody preparations inhibited bacterial migration compared to that of isotype controls.
c Shown is bacterial motility inhibition in liquid medium. The data presented in this column represent a summary of data from Fig. 2 and from Movies S2 to S4 in the supplemental
material.
d SEM, scanning electron microscopy; W, wrinkling; B, blebbing; T, tethering. The data presented in this column represent a summary from Fig. 3, 4, and 5.
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2D6 IgA promotes bacterial cross-linking and induces
changes in V. cholerae surface morphology. V. cholerae’s single
polar flagellum generates extraordinary torque, as it can propel
the bacterium at speeds of 70 m/s (33). To examine how a
single MAb directed against OPS interferes with V. cholerae flagel-
lum-mediated motility in such a rapid and potent manner, we
treated V. cholerae with 2D6 IgA and imaged the cells by SEM.
Mid-log-phase cultures of V. cholerae O395 were incubated with
2D6 IgA for 20, 60, or 120 min, after which they were collected by
vacuum filtration, fixed, critical point dried, coated with gold, and
visualized by SEM. Control (Sal4-treated) V. cholerae O395 cells
were evenly distributed across the porous filter with no evidence
of bacterial agglutination or clumping (Fig. 3A and B). In general,
the surfaces of the bacteria were smooth and relatively devoid of
blebs. Furthermore, formation of septa was apparent on numer-
ous bacterial bodies, indicating that the cells were undergoing
division at the time of chemical fixation. We only observed flagella
on a small fraction of V. cholerae cells, possibly as a result of mild
shear forces encountered during processing for SEM (34).
The appearance of cells treated with 2D6 IgA was strikingly
different. As early as 20 min following 2D6 IgA exposure, V. chol-
erae cells were completely aggregated—likely a result of antibody-
mediated cross-linking (Fig. 3C and D). Flagella were wrapped
around and sandwiched between neighboring bacterial cells as
well as entangled, looped, and knotted with other flagella (Fig.
3D). The formation of cell-flagellum and flagellum-flagellum in-
teractions may explain, in part, the rapid capacity of 2D6 IgA to
promote the V. cholerae motility arrest and agglutination we ob-
served by video light microscopy.
The surfaces of the 2D6-treated V. cholerae cells were also no-
tably more wrinkled than those of the Sal4-treated cells, and there
was a significant increase in the number of membrane-associated
blebs (Fig. 3D and 4). Blebs observed on the surface of control
(Sal4-treated) cells tended to be small and more homogenous in
size (40 to 60 nm in diameter), whereas following 2D6 IgA treat-
ment, the surface blebs were larger and more heterogeneous in
size, ranging from 30 to 160 nm in diameter. By 120 min, 2D6
IgA-treated V. cholerae cells remained tethered to each other via
flagella and assumed a crusty appearance (Fig. 3E). There was also
a notable increase in debris associated with the cell poles and filter
surfaces, possibly indicative of sloughing of blebs or other surface
materials. Collectively, these images suggest that 2D6 may induce
a form of outer membrane stress in V. cholerae, despite the fact
that 2D6 IgA is neither bactericidal nor bacteriostatic (data not
shown).
Motility arrest and changes in surface morphology induced
by monovalent 2D6 Fab fragments. To further examine the
mechanism by which 2D6 promotes motility arrest and altera-
tions in V. cholerae surface morphology independent of antibody-
mediated cross-linking, we generated monovalent 2D6 Fab frag-
ments. Mid-log-phase cultures of V. cholerae GFP-expressing
strain RT4273 were mixed with 2D6 IgA, 2D6 IgG, or 2D6 Fab
fragments, spotted onto glass microscope slides, and then imaged
by video fluorescence microscopy, as described above. As ob-
served previously, 2D6 IgA treatment arrested V. cholerae motility
within 5 min and was accompanied by agglutination. By 30 min,
cultures treated with IgA 2D6 were completely immobilized (see
Movie S2 in the supplemental material). 2D6 IgG had a similar,
albeit slower effect on V. cholerae motility arrest (Table 1; see
Movie S3 in the supplemental material), indicating that the di-
meric nature of 2D6 IgA (as opposed to the monomeric nature of
2D6 IgG) likely contributes to 2D6’s biological activity. Finally,
although 2D6 Fab fragments did not induce agglutination or teth-
ering of V. cholerae, they were able to promote motility arrest.
Within 5 min, approximately 50% of Fab-treated cells were im-
mobilized, and by 20 min, 70% were nonmotile (Table 1; see
Movie S4 in the supplemental material).
To investigate whether 2D6 Fab fragments were sufficient to
induce changes in V. cholerae surface morphology, mid-log-phase
cultures of V. cholerae were treated with 2D6 Fab fragments and
then subjected to SEM, as described above. As expected, treatment
of cells with 2D6 IgA induced agglutination, flagellar interactions,
surface blebbing, and wrinkling. We observed that treatment of V.
cholerae with 2D6 Fab fragments elicited membrane blebs and
wrinkles that were virtually identical to those observed on 2D6
IgA-treated cells (Fig. 5). Between 60 and 120 min, Fab-treated
cells assumed a crusty appearance similar to what we had observed
following IgA 2D6 treatment (Fig. 3E). These data demonstrate
that binding of 2D6 to the surface of V. cholerae, in the absence of
cross-linking or agglutination, is sufficient to arrest bacterial mo-
tility and to promote changes in surface morphology.
We next employed the mouse ligated-ileal-loop assay to inves-
tigate the effects of 2D6 Fabs on the ability of V. cholerae to colo-
nize epithelial surfaces. As expected, 2D6 Fab-treated cells were
not overtly aggregated in the lumenal space (Fig. 1C), which was in
stark contrast to what was observed when bacteria where treated
with 2D6 IgA. Moreover, we observed that bacteria treated with
2D6 Fabs were distributed along the length of individual intestinal
villi and were present in crypts, demonstrating that the Fab frag-
ments alone (and presumably their effects on motility and surface
morphology) were not sufficient to prevent bacterial access to
target niches. However, one caveat to these studies is that the
mouse ligated-ileal-loop assay is not necessarily an ideal model
system with which to assess the contribution of flagellum-based
motility, as evidenced by the fact that a V. cholerae 
flaA mutant
was similar to wild-type O395 in its ability to visibly associate with
villus and crypt epithelium (see Fig. S1 in the supplemental mate-
rial).
DISCUSSION
Although there is mounting evidence that OPS-specific IgA anti-
bodies are the primary contributor to mucosal immunity against
V. cholerae, the mechanisms by which these antibodies interfere
with V. cholerae’s ability to colonize the intestinal epithelium re-
main poorly understood (3, 9, 17–19, 35). In this study, we exam-
ined the interaction between V. cholerae O395 and 2D6, a murine
polymeric IgA MAb directed against the nonreducing terminal
residue of Ogawa OPS (11, 12, 25). 2D6 was the first monoclonal
IgA shown to be sufficient to protect suckling mice from a lethal
challenge with V. cholerae and, therefore, serves as an invaluable
tool to elucidate the impact of secretory IgA antibodies on V.
cholerae virulence and pathogenesis (12).
Using a mouse ligated-ileal-loop assay, we observed that 2D6
IgA limited the ability of V. cholerae to visibly associate with the
intestinal epithelium, particularly within the crypt regions.
Whereas control bacteria were uniformly distributed across the
apical aspects of the small intestine, including the crypts, 2D6-
treated cells were observed as large aggregates and microclusters
largely confined to the lumen. Under the same experimental con-
ditions, monovalent 2D6 Fab fragments did not noticeably inter-
Levinson et al.
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FIG 3 SEM analysis reveals that 2D6 IgA treatment induces membrane wrinkling, blebbing, and flagellar tethering. Mid-log-phase cultures of V. cholerae O395 were
treated with Sal4 IgA (A and B) or 2D6 IgA (C to E). Cells were collected at 20 min (A and C), 60 min (B and D), or 120 min (E) following antibody treatment
and processed for SEM, as described in Materials and Methods. (A and B) Control-treated V. cholerae cells were evenly distributed across the porous filter
membrane, and there was no evidence of bacterial agglutination or clumping. (C to E) Compared to control cells, 2D6 IgA-treated V. cholerae cells were
aggregated (compare arrows in panels A and C) and were notably more wrinkled (compare panels B and D). In addition, following 60 min (D) and 120 min (E)
of treatment with 2D6 IgA, there was notable flagellum-flagellum cross-linking, flagellar entanglement with neighboring bacterial bodies, and even flagellar
knotting (arrows). (D) V. cholerae cells treated with 2D6 IgA were also associated with an increased number of surface blebs (arrow). Note that TCP was not
observed in these images, because the bacteria were cultured under non-toxin-inducing conditions. Scale bars: panels A and C, 2 m; panels B and D, 200 nm;
panel E, 1 m.
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fere with V. cholerae-epithelial contact, underscoring the impor-
tance of agglutination in limiting bacterial association with the
intestinal epithelium, at least in the mouse ligated-ileal-loop
model. In line with what is known about S-IgA in the human host,
it would be expected that 2D6 IgA-mediated cross-linking of V.
cholerae would result in bacterial entrapment in mucus and clear-
ance from the intestine via peristalsis (11, 12, 36). The secretory
component (SC), which has known mucophilic properties, would
further enhance 2D6 IgA’s capacity to ensnare V. cholerae within
the mucus layer (37).
The extent to which agglutination contributes to protective
immunity to V. cholerae during infection (as opposed to the ligat-
ed-ileal-loop assay) remains unresolved (38). Agglutination is
likely a rare event in vivo, considering that formation of bacte-
rium-antibody cross-linked complexes is achieved only when the
stoichiometry of bacteria to specific antibody is optimal. Even a
relatively high inoculum of V. cholerae (106) would be expected
to become diluted considerably within the contents of the stom-
ach and further dispersed along the length of the proximal small
intestine, making the likelihood of forming bacterium-antibody
bridges slim. Moreover, there may even be less opportunity for
bacterial cross-linking to occur than previously assumed in light
of recent work indicating that colonization of epithelial surfaces
by V. cholerae is initiated by single seeder cells and not microclus-
ters (6).
With that in mind, the observation that 2D6 IgA inhibits V.
cholerae O395 motility in vitro should be considered a possible
determinant of protective immunity in vivo. By fluorescence dig-
ital video microscopy, we noted that exposure of V. cholerae to
2D6 IgA resulted in a majority (85%) of cells becoming immo-
bilized within 5 min; by 30 min the entire cell population had
come to a standstill. Although Gustafsson and Holme recognized
the inhibition of V. cholerae motility by anti-LPS antibodies 30
years ago (39), it is only recently that motility arrest has been
associated with mucosal protection. Specifically, Bishop and Ca-
milli demonstrated by dark-field microscopy that milk-derived
mouse polyclonal anti-LPS IgA antibodies inhibited bacterial mo-
tility in aqueous medium and that this activity correlated with
protection in the neonatal mouse model (13). They also noted that
that motility arrest appeared to precede agglutination, suggesting
that the two phenomena (i.e., motility arrest and agglutination)
are in fact distinct events.
Our study advances the work by Bishop and Camilli in two
important ways. First, we established that targeting IgA to a single
FIG 4 Increased blebs on the surface of V. cholerae following 2D6 IgA treatment. Mid-log-phase cultures of V. cholerae O395 were treated with 2D6 IgA for 60
min and then processed for SEM, as described in the legend to Fig. 3. (A) Surface blebs (arrows) on cells following 2D6 IgA treatment. Scale bar, 1 m. (B)
Quantitation of blebs per bacterium in control or 2D6 IgA-treated V. cholerae. In general, blebs were heterogeneous in size (30 to 160 m) following 2D6 IgA
treatment compared to those in control cells, where they were less numerous and more homogenous (40 to 60 m). Student’s t test was used to determine
significance (P  0.0001).
FIG 5 Treatment of V. cholerae with 2D6 Fab fragments results in membrane wrinkles and blebs. Mid-log-phase cultures of V. cholerae O395 were treated with
2D6 Fab fragments for 60 min and then processed for SEM, as described in the legend to Fig. 3. (A) Control cell with relatively smooth surface pattern and single
polar flagellum. (B and C) Cells treated with 2D6 Fab fragments were wrinkled and had numerous blebs (arrows), similar to those observed following 2D6 IgA
treatment. Moreover, there was notable debris on the filter surface (arrowheads) that was absent from the control cells. Scale bars: panels A and B, 1 m; panel
C, 200 nm.
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epitope on the serotype-specific terminal residue of Ogawa OPS is
sufficient to promote V. cholerae motility arrest. Previously only
polyclonal IgA antibodies of mixed epitope specificity and un-
known concentrations had been evaluated in motility studies (13).
2D6 is one of only two murine monoclonal IgAs against V. chol-
erae LPS that have been described in the literature. The other,
MAb ZAC-3, recognizes an epitope within the lipid A and/or core
regions of LPS common to Ogawa and Inaba (25). Interestingly,
our preliminary studies suggest that ZAC-3 is significantly more
effective than 2D6 at inhibiting bacterial motility in vitro (K.
Levinson, S. Giffen, and N. Mantis, unpublished results), raising
the possibility that epitope specificity may influence antibody po-
tency. Defining the relationships between epitope specificity, mo-
tility arrest, and, ultimately, protective immunity could have im-
portant implications for cholera vaccine development and
assessment. For example, Johnson and colleagues recently re-
ported that OPS and LPS serum and fecal antibody responses in
convalescent individuals largely mirror each other but that vibrio-
cidal activity was associated with OPS (35). It would be interesting
to evaluate the same samples with respect to motility inhibition.
We also substantiated Bishop and Camilli’s claim that anti-
body-mediated agglutination and motility arrest are in fact sepa-
rable phenomena (13). Specifically, we demonstrated by video
microscopy that exposure of V. cholerae to 2D6 Fab fragments
resulted in 50% motility inhibition within 5 min and 75%
inhibition by 20 min. We reason that the fact that 2D6 Fab frag-
ments did not arrest bacterial motility to the same degree as 2D6
IgA is indicative of there being at least two mechanisms by which
IgA interferes with V. cholerae motility. The first is mechanical in
nature and involves the “tethering” and cross-linking of V. chol-
erae flagella. SEM analysis of 2D6 IgA-treated cells revealed fla-
gella wrapped around neighboring bacterial bodies and entan-
gled/knotted with other flagella. Flagellar entanglement is not
simply an artifact of sample preparation, as we also observed evi-
dence of flagellar tethering via video microscopy. It is not surpris-
ing to us that flagellar entanglement would occur in culture, con-
sidering that the bacteria swim in excess of 70 m/s, and their
flagella rotate at 1,700 revolutions/s (33, 40). Moreover, 2D6 has
been shown to coat V. cholerae’s LPS-sheathed flagellum and
would therefore be fully capable of cross-linking the flagellum to
other flagella or bacterial bodies (12). What remains unclear is
how IgA overcomes the shear force associated with flagellar rota-
tion that would be necessary to promote flagellum-flagellum or
flagellum-cell body interactions.
We postulate that the second mechanism of IgA-mediated in-
hibition of V. cholerae motility is due to direct antibody binding to
the V. cholerae body, which in turn may trigger an outer mem-
brane stress response and/or feedback signaling via the flagellum.
While speculative at this stage, the results presented here are rem-
iniscent of studies we have conducted with S. Typhimurium in
which a monoclonal IgA (Sal4) specific for the O antigen is suffi-
cient to paralyze the bacterium within a matter of minutes (23).
Sal4 also affects type 3 secretion system (T3SS) activity, membrane
potential, and permeability, as well as exopolysaccharide produc-
tion (21, 24). Moreover, the association of Sal4 with the S. Typhi-
murium O antigen induces distinct ultrastructural changes in the
bacterium’s surface morphology, including wrinkles and blebs
that are nearly identical to those observed on the surface of V.
cholerae following 2D6 treatment (20). Membrane bleb formation
in particular is indicative of membrane stress (41). Preliminary
transcriptome-based studies are in accordance with the hypothe-
sis that anti-LPS antibodies like 2D6 and ZAC-3 IgA trigger an
outer membrane stress response in V. cholerae (K. Levinson and
N. Mantis, unpublished results).
The studies described in this report were routinely conducted
under what are considered non-toxin-inducing conditions (e.g.,
pH 7.0 and 37°C with aeration) (42, 43). As a result, the bacteria
were most certainly devoid of toxin-coregulated pilus (TCP),
which is involved in attachment of V. cholerae to the intestinal
epithelium. TCP also promotes an autoagglutination phenotype
that has been proposed to facilitate microcolony formation on
mucosal surfaces. It is interesting to speculate how 2D6 IgA might
affect TCP-mediated autoagglutination and attachment in vivo,
considering that TCP forms long filaments that extend well be-
yond the bacterial surface, compared to 2D6 IgA, which is (theo-
retically) only 28 nm in length (44) and would simply cap individ-
ual LPS molecules (45). The fact that 2D6 IgA protects suckling
mice from V. cholerae grown under TCP-inducing conditions is
evidence that 2D6 trumps TCP, but how exactly that occurs at the
cellular and molecular levels remains to be elucidated.
In summary, we propose that protection of the intestinal epi-
thelium from V. cholerae infection by S-IgA may be multifactorial,
including antibody-induced agglutination, motility arrest, and
possibly outer membrane stress. Defining the exact contribu-
tion(s) of each of these activities in mucosal immunity will have
important implications for vaccine development and assessment.
It is clear that vibriocidal activity based on LPS-specific serum IgG
and IgM levels in convalescent and vaccinated individuals is a
useful but incomplete measure of protection (1, 3, 9). Similarly,
determination of total LPS-specific serum IgA and S-IgA titers
may reveal only part of the story; we would argue that the “quality”
of secretory antibodies might be more important than the actual
quantity of antibodies. It is for that reason that it is essential to
further identify functional activities associated with protective
monoclonal IgA antibodies and then assess these activities on pri-
mary polyclonal antibody mixtures. Ultimately, a better under-
standing of how LPS-specific IgA antibodies interfere with the
capacity of V. cholerae to colonize the intestinal epithelium will
assist in the design of better targeted vaccine strategies and, possi-
bly, the development of surrogate in vitro assays that can more
effectively predict the protective efficacy of the mucosal antibody
responses elicited by candidate cholera vaccines.
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